Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.
Chronic kidney disease
Complement
Dialysis
Innate immunity
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
21
08
2020
accepted:
19
11
2020
pubmed:
12
12
2020
medline:
19
8
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Various studies have reported the importance of complement regulators in preventing mesothelial damage during peritoneal dialysis (PD). Its assessment, however, is limited in clinical practice due to the lack of easy access to the peritoneal membrane. Recently, a soluble form of the complement regulatory protein CD59 (sCD59) has been described. We therefore aimed to investigate the role of sCD59 in PD. Plasma sCD59 was measured in 48 PD patients, 41 hemodialysis patients, 15 non-dialysis patients with chronic kidney disease and 14 healthy controls by ELISA (Hycult; HK374-02). Additionally, sCD59 and sC5b-9 were assessed in the peritoneal dialysate. sCD59 and sC5b-9 were detectable in the peritoneal dialysate of all patients, and marginally correlated (r = 0.27, P = 0.06). Plasma sCD59 levels were significantly higher in PD patients than in patients with chronic kidney disease and healthy controls, but did not differ from hemodialysis patients. During follow-up, 19% of PD patients developed peritoneal membrane failure and 27% of PD patients developed loss of residual renal function. In adjusted models, increased sCD59 levels in the dialysate (HR 3.44, 95% CI 1.04-11.40, P = 0.04) and in plasma (HR 1.08, 95% CI 1.01-1.17, P = 0.04) were independently associated with the occurrence of peritoneal membrane failure. Higher plasma levels of sCD59 were also associated with loss of residual renal function (HR 1.10, 95% CI 1.04-1.17, P < 0.001). Our study suggests that sCD59 has potential as a biomarker to predict peritoneal membrane function and loss of residual renal function in PD, thereby offering a tool to improve patient management.
Identifiants
pubmed: 33306183
doi: 10.1007/s40620-020-00934-7
pii: 10.1007/s40620-020-00934-7
pmc: PMC8192357
doi:
Substances chimiques
Biomarkers
0
CD59 Antigens
0
Dialysis Solutions
0
CD59 protein, human
101754-01-2
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
801-810Références
Marshall MR (2020) The benefit of early survival on PD versus HD—why this is (still) very important. Perit Dial Int. https://doi.org/10.1177/0896860819895177
doi: 10.1177/0896860819895177
pubmed: 32067571
Aufricht C, Beelen R, Eberl M, Fischbach M, Fraser D, Jörres A et al (2017) Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. Kidney Int 92(4):824–835
doi: 10.1016/j.kint.2017.02.037
Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortíz A (2008) Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int. 73:108. https://doi.org/10.1038/sj.ki.5002600
doi: 10.1038/sj.ki.5002600
Krediet RT (2013) Peritoneal dialysis: from bench to bedside. Clin Kidney J 6(6):568–577
doi: 10.1093/ckj/sft122
Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB et al (2013) Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 24(12):2071–2080
doi: 10.1681/ASN.2013030314
Schmidt CQ, Lambris JD, Ricklin D (2016) Protection of host cells by complement regulators. Immunol Rev 274(1):152–171
doi: 10.1111/imr.12475
Barbano G, Cappa F, Prigione I, Tedesco F, Pausa M, Gugliemino R et al (1999) Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis. Adv Perit Dial 15:253–257
pubmed: 10682113
Sei Y, Mizuno M, Suzuki Y, Imai M, Higashide K, Harris CL et al (2015) Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Mol Immunol 65(2):302–309
doi: 10.1016/j.molimm.2015.02.005
Mizuno M, Ito Y, Mizuno T, Harris CL, Suzuki Y, Okada N et al (2012) Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. AJP Ren Physiol 302(10):F1245–F1251
doi: 10.1152/ajprenal.00652.2011
Mizuno T, Mizuno M, Morgan BP, Noda Y, Yamada K, Okada N et al (2011) Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant 26(6):1821–1830
doi: 10.1093/ndt/gfq683
Kitterer D, Biegger D, Segerer S, Braun N, Alscher MD, Latus J (2017) Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis. PLoS ONE 12:5. https://doi.org/10.1371/journal.pone.0177487
doi: 10.1371/journal.pone.0177487
Brasoveanu LI, Fonsatti E, Visintin A, Pavlovic M, Cattarossi I, Colizzi F et al (1997) Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 100(5):1248–1255
doi: 10.1172/JCI119638
Lehto T, Honkanen E, Teppo AM, Meri S (1995) Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 47(5):1403–1411
doi: 10.1038/ki.1995.197
Väkevä A, Lehto T, Takala A, Meri S (2000) Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction. Scand J Immunol 52(4):411–414
doi: 10.1046/j.1365-3083.2000.00783.x
Faria B, da Costa MG, Poppelaars F, Franssen CFM, Pestana M, Berger SP et al (2019) Administration of intravenous iron formulations induces complement activation in-vivo. Front Immunol 2019:10. https://doi.org/10.3389/fimmu.2019.01885
doi: 10.3389/fimmu.2019.01885
Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CFM, Seelen MAJ (2016) Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 14:236. https://doi.org/10.1186/s12967-016-0995-5
doi: 10.1186/s12967-016-0995-5
pubmed: 27495980
pmcid: 4974702
Poppelaars F, Gaya da Costa M, Berger SP et al (2016) Erratum to: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 14:245. https://doi.org/10.1186/s12967-016-1004-8
doi: 10.1186/s12967-016-1004-8
pubmed: 27557787
pmcid: 4997692
Hempel JC, Poppelaars F, Gaya da Costa M, Franssen CFM, de Vlaam TPG, Daha MR, Berger SP, Seelen MAJ, Gaillard CAJM (2017) Distinct in vitro Complement Activation by Various Intravenous Iron Preparations. Am J Nephrol 45:49–59. https://doi.org/10.1159/000451060
doi: 10.1159/000451060
pubmed: 27889746
Blake PG, Bargman JM, Scott Brimble K, Davison SN, Hirsch D, McCormick BB et al (2011) Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Perit Dial Int 31(2):218–239
doi: 10.3747/pdi.2011.00026
Moreira CL, Cunha L, Correia S, Silva F, Castro A, Tavares J et al (2020) Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? Brazilian J Nephrol 42(1):31–37
doi: 10.1590/2175-8239-jbn-2019-0007
Cheng LT, Chen W, Tang W, Wang T (2006) Residual renal function and volume control in peritoneal dialysis patients. Nephron Clin Pract 104:1. https://doi.org/10.1159/000093670
doi: 10.1159/000093670
Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W (2000) A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 11:12
doi: 10.1681/ASN.V11122344
Kinoshita T (2018) Congenital defects in the expression of the glycosylphosphatidylinositol-anchored complement regulatory proteins CD59 and decay-accelerating factor. Semin Hematol 55(3):136–140
doi: 10.1053/j.seminhematol.2018.04.004
Qin X, Hu W, Song W, Grubissich L, Hu X, Wu G et al (2009) Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol 84(2):65–70
doi: 10.1002/ajh.21319
Brooimans RA, van der Ark AAJ, Tomita M, van Es LA, Daha MR (1992) CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol 22(3):791–797
doi: 10.1002/eji.1830220324
Reddingius RE, Schröder CH, Daha MR, Willems HL, Koster AM, Monnens LA (1995) Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int. 15(1):49–53
doi: 10.1177/089686089501500110
Catizone L, Cocchi R, Gagliardini R, Rovinetti C, Fusaroli MZP (1989) Peritoneal equilibration curve for beta-2-microglobulin (B2M) in CAPD patients. Adv Perit Dial 5:200–203
pubmed: 2577412
Landi APG, Wilson AB, Davies A, Lachmann PJ, Ferriani VPL, Seilly DJ et al (2003) Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex. Immunol Lett 90(2–3):209–213
doi: 10.1016/j.imlet.2003.07.001
Bartosova M, Schaefer B, Bermejo JL, Tarantino S, Lasitschka F, Macher-Goeppinger S et al (2018) Complement activation in peritoneal dialysis-induced arteriolopathy. J Am Soc Nephrol 29(1):268–282
doi: 10.1681/ASN.2017040436
Zavvos V, Buxton AT, Evans C, Lambie M, Davies SJ, Topley N et al (2017) A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney Int 92(4):988–1002
doi: 10.1016/j.kint.2017.03.030
Kumar B, Cashman SM, Kumar-Singh R (2018) Complement-mediated activation of the NLRP3 inflammasome and its inhibition by AAV-mediated delivery of CD59 in a model of uveitis. Mol Ther 26(6):1568–1580
doi: 10.1016/j.ymthe.2018.03.012
Betjes MGH, Habib MS, Struijk DG, Lopes Barreto D, Korte MR, Abrahams AC et al (2015) Encapsulating peritoneal sclerosis is associated with T-cell activation. Nephrol Dial Transplant 30(9):1568–1576
doi: 10.1093/ndt/gfv092
Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B (2001) Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 16(11):2240–2245
doi: 10.1093/ndt/16.11.2240